CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
The move strengthens GBL’s clinical-stage presence in the United States
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
While Merck can appeal, Halozyme said it expects the order to hold
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Subscribe To Our Newsletter & Stay Updated
